Navigation Links
Does the existing standard of care supply energy sources to brain tumor cells?
Date:7/14/2010

Chestnut Hill, Mass. (7/14/2010) The medical standard of care comprised of surgery, radiation and chemotherapy for the most common form of brain cancer triggers a number of biological responses that may actually feed the energy metabolism that supports the disease, according to Boston College researchers writing in the journal Lancet Oncology.

The deadly glioblastoma multiforme leaves the average patient a median survival of about a year from diagnosis. Just three percent of patients afflicted with the fast-moving brain cancer survive 36 months. The standard of care for the treatment of the disease has not changed markedly since it was established 50 years ago.

But the effects of surgery, radiation and chemotherapy produce a range of biochemical responses in the brain that can fuel tumor cell survival at the same time doctors are attempting to eradicate the disease, according to Boston College Professor of Biology Thomas Seyfried, whose lab has researched ways to deny energy to cancer cells.

"All tumors, regardless of where they are located, require two major fuels for survival: glucose and glutamine," said Seyfried, a specialist in lipid biochemistry. "As long as tumor cells have access to these energy molecules, they will survive. If you give them a lot of these molecules, they will survive even better."

The three components of cerebral cancer care may play a role in providing tumor cells with the metabolic fuels they need to survive. While these treatments reduce tumor growth over the short term, radiation and certain chemotherapies could actually contribute to the high recurrence of these deadly tumors.

A growing body of research over the past decade, according to Seyfried, now shows the processes of radiation and chemotherapy can serve to increase the supply of glucose and glutamine, leading to conditions favorable to tumor cell survival and growth.

Furthermore, infection-fighting tumor-assoc
'/>"/>

Contact: Ed Hayward
ed.hayward@bc.edu
617-552-4826
Boston College
Source:Eurekalert

Page: 1 2

Related biology news :

1. Study points to new uses, unexpected side effects of already existing drugs
2. Stress signals link pre-existing sickness with susceptibility to bacterial infection
3. Complications early in pregnancy or in previous pregnancies adversely affect existing or subsequent pregnancies
4. Nature cover study provides new standards for reliable fisheries
5. Gold Standard/Elsevier offers timely, reliable drug pricing data, including average wholesale price
6. Meet Phannie, NISTs standard phantom for calibrating MRI machines
7. Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing
8. Researchers develop standard of care for breast cancer survivors with lymphedema
9. Stent grafts top gold standard balloon angioplasty for dialysis patients
10. Quality and safety of infant formulas, functional foods enhanced by new standards
11. U. of I. business instructional facility achieves top green standard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today announced the ... ancestry of individuals from across the United States ... four hundred years ago, the United States ... different continents. This study illuminates how American history and the ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced today its ... confirm its adherence to current U.S. Food and Drug ... regulated smart device and smart phone application trials utilizing ... "HITLAB is determined to improve global healthcare ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Infectious Diseases (NIAID), part of the National Institutes ... $80 million for two new Regional Centers of ... (RCE). The grants to the University of California, ... the completion of a national network of academic ...
... with implications for pandemic influenza, a new study reports for ... virus can spread from poultry to humans. The research ... Infectious Diseases, now available online. , Crossing the species barrier ... virus with pandemic potential. Previous studies have focused on the ...
... problem of "super-bugs" - bacteria that have become resistant ... high rate of antibiotic prescribing in hospitals contributes to ... antibiotics, an even more important factor contributing to such ... access international medical journal PLoS Medicine, is the use ...
Cached Biology News:New NIAID grants strengthen national biodefense and emerging infectious diseases research network 2Less virulent strains of avian influenza can infect humans 2Agricultural antibiotic use contributes to 'super-bugs' in humans 2
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 ... technologies such as the Bioruptor® and complete solutions ... system for chromatin immunoprecipitation, alleviating the need for ... and controls needed for ChIP of histones or ...
(Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Bulletin Board: ACCP) announced today that it will make ... Conference to be held,November 10-12, 2008 at the New ... scheduled to speak on Tuesday, November 11, 2008 at ... and discuss the Company,s,product opportunities., The presentation will ...
... ROCKVILLE, Md., Nov. 6 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases, today,reported ... September 30,2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), ... approximately $3,501,000,versus $3,520,000 for the comparable period a ...
... safety profile of Ranexa -, - Conference ... -, PALO ALTO, Calif., Nov. 6 ... that the U.S. Food and Drug,Administration (FDA) has ... extended-release tablets) for the treatment of,chronic angina. The ...
Cached Biology Technology:Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference 2EntreMed Reports Third Quarter 2008 Financial Results 2EntreMed Reports Third Quarter 2008 Financial Results 3EntreMed Reports Third Quarter 2008 Financial Results 4EntreMed Reports Third Quarter 2008 Financial Results 5FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 2FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 3FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 4FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 5
... 400 unique human proteins on a ... proteins, a cross section of all ... for high-quality results. Additional control proteins ... high validity and reproducibility., ,UNIchip protein ...
...
... The benchmark for analytical performance ... ease-of-use and the ultimate in ... Varian 810-MS features include: ... optics minimize,interferences, providing reliable, routine, ...
... it uses a deep-UV deuterium bulb, which provides ... a shutter (controlled via a TTL signal or ... DH-2000 Deuterium Tungsten Halogen Light Source combines the ... sources in a single optical path. The combined-spectrum ...
Biology Products: